Safety and tolerability of subcutaneous trastuzumab for the adjuvant treatment of human epidermal growth factor receptor 2-positive early breast cancer: SafeHer phase III study's primary analysis of 2573 patients

J. Gligorov, B. Ataseven, M. Verrill, M. De Laurentiis, K. H. Jung, H. A. Azim, N. Al-Sakaff, S. Lauer, M. Shing, X. Pivot, Dhurata Koroveshi, Kamel Bouzid, Monica Casalnuovo, Diana Cascallar, Ernesto Pablo Korbenfeld, Patricia Bastick, Jane Beith, Maree Colosimo, Michael Friedlander, Vinod GanjuMichael Green, Kevin Patterson, Andrew Redfern, Gary Richardson, Timur Ceric, Kecman Gordana, Carlos Augusto Beato, Marcela Ferrari, Roberto Hegg, Vanessa Helena, Gustavo Fernando Ismael, Alvaro Edson Lessa, Max Mano, Alessandra Morelle, Jose Alberto Nogueira, Konstanta Timcheva, Antoaneta Tomova, Maya Tsakova, Ani Zlatareva-Petrova, Jamil Asselah, Hazem Assi, Christine Brezden-Masley, Stephen Chia, Ori Freedman, Mohammed Harb, Anil Abraham Joy, Swati Kulkarni, Catherine Prady, Alejandro Andres Acevedo Gaete, Mohamed Idris, the SafeHer Study Group

Research output: Contribution to journalArticlepeer-review

27 Citations (Scopus)

Fingerprint Dive into the research topics of 'Safety and tolerability of subcutaneous trastuzumab for the adjuvant treatment of human epidermal growth factor receptor 2-positive early breast cancer: SafeHer phase III study's primary analysis of 2573 patients'. Together they form a unique fingerprint.

Medicine & Life Sciences